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BACKGROUND: NEDD8 ultimate buster 1 (NUB1) is an interferon (IFN)-inducible protein that downregulates NEDD8 expression and
its conjugation system. Although overexpression of NUB1 induces a growth-inhibitory effect in cells, the mechanisms underlying the
anti-mitogenic actions of NUB1 in cancer cells remain uncertain. We investigated the anti-cancer effects of NUB1 in human renal cell
carcinoma (RCC) cells.
METHODS: Nine human RCC cells were used for this study. The proliferation of RCC cells exposed to IFN-a was measured by water-
soluble tetrazolium salt assay. The expression level of NUB1 in cells was measured by quantitative reverse transcriptase PCR or
western blot analysis. Apoptosis and cell-cycle analysis were performed by flow cytometry. Silencing of NUB1 was performed using a
small interfering RNA.
RESULTS: Both NUB1 messenger RNA and protein were significantly induced by IFN-a in seven out of nine selected RCC cell lines, and
the NUB1 expressions induced by IFN-a correlated positively with cell growth inhibition. Overexpression of NUB1 remarkably
induced S-phase transition during cell cycle and apoptosis in IFN-a-resistant A498 cells, in which NUB1 is not induced by IFN-a.
The expression levels of two cell-cycle regulator proteins, cyclin E and p27, were increased under the aforementioned conditions.
The knockdown of NUB1 enhanced cell proliferation of IFN-a-resistant A498 cells and suppressed IFN-a-induced growth inhibition
in IFN-a-sensitive 4TUHR cells.
CONCLUSION: NUB1 may be a key factor involved not only in cell growth inhibition by IFN-a in RCC cells but also in the anti-cancer
effect against IFN-a-resistant RCC cells.
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Renal cell carcinoma (RCC) is the most common cancer of the
kidney (Parkin et al, 2005). Approximately 30% of patients with
RCC present with metastatic disease (Motzer et al, 1996; Lam et al,
2005), and the 5-year survival rate for those with metastatic RCC is
o10% (Motzer et al, 1996). Immunotherapy based on interferon
alpha (IFN-a) and/or interleukin-2 has been widely adopted as the
first-line treatment for metastatic RCC and clinical benefits
including long-term complete remission have been demonstrated,
but the prognosis of these patients is still poor (Negrier et al, 1998;
McDermott et al, 2005).
Recently, several alternative treatments were developed for
metastatic RCC. Vascular endothelial growth factor (VEGF) is a
potent pro-angiogenic protein that is responsible for increased
vasculature and tumour growth in RCC. Fundamentally, a
mutation in the von Hippel–Lindau tumour-suppressor gene
induces overexpression of VEGF through accumulation of
hypoxia-inducible factor (HIF)-1 in RCC (Maxwell et al, 1999;
Kerbel, 2008). Several novel agents that inhibit the VEGF signalling
cascade, such as sorafenib, sunitinib and bevacizumab, have
been found to exert significant anti-tumour effects and provide
meaningful clinical benefits (Escudier et al, 2007; Hudes et al,
2007; Motzer et al, 2007; Rini et al, 2008). Furthermore,
temsirolimus and everolimus, inhibitors of the mammalian target
of rapamycin (mTOR), which block the phosphoinositide 3-kinase
(PI3K)/AKT signalling pathway involved in numerous cellular
functions including cell proliferation, survival and angiogenesis,
have been found to be effective agents against advanced RCC in the
clinical setting (Hudes et al, 2007; Amato et al, 2009). Although
molecular targeting therapies against the VEGF or mTOR
signalling pathway have revolutionised the treatment of advanced
RCC, no curative therapy has yet been established. Moreover,
although IFN-a is the classic standard for treating RCC, the anti-
tumour action of IFN-a exerted through a direct inhibition of
tumour growth and biological response modifiers remains to be
clarified. Hence, identifying the molecules critical for immuno-
therapy with IFN-a is still crucial to developing treatments for
metastatic RCC.
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forms conjugates with cullin family proteins and thereby
activates an Skp1-Cullin-F-box (SCF) ubiquitin protein ligase
complex that catalyses the ubiquitination of many cell-
cycle regulators, for example, cyclin E, p21, p73 and p27 (Singer
et al, 1999; Podust et al, 2000; Wang et al, 2005; Watson et al,
2006).
NEDD8 ultimate buster 1 (NUB1) is a NEDD8-interacting
protein composed of 601 amino-acid residues with a calculated
molecular mass of 69.1kDa. It is an IFN-inducible protein and
predominantly localises in the nucleus. Biologically, NUB1 recruits
NEDD8 and its conjugates to the proteasome for degradation and
negatively regulates the NEDD8 conjugation system (Kamitani
et al, 2001; Kito et al, 2001; Tanaka et al, 2003). Furthermore,
NUB1 is expressed in some cancer cell lines, including rectal
adenocarcinoma, neuroblastoma, malignant lymphoma, cervical
adenocarcinoma and RCC (Kito et al, 2001). Kito et al have also
shown that the expression of NUB1 is induced by IFN-b in certain
cell lines and that exogenous overexpression of NUB1 inhibits
proliferation of U2OS cells, which are deficient in endogenous
NUB1 expression (Kito et al, 2001). Recently, NUB1 has been
reported to inhibit the formation of inclusions such as the Lewy
bodies seen in brains of patients with Parkinson’s disease (Tanji
et al, 2006). As the expression of NEDD8 is downregulated by
NUB1, the expression level of NUB1 may control many important
biological events, including cell-cycle progression. However, the
biological functions of NUB1 in cancer cells remain largely
unknown.
We investigated the relations of NUB1 protein induction by
IFN-a with growth inhibition of cells exposed to IFN-a and the
biological actions of NUB1 (e.g., cell-cycle regulation, induction of
apoptosis) in RCC cell lines.
MATERIALS AND METHODS
Cell lines and cell culture
Human RCC cell lines ACHN (CRL-1611), Caki-1(HTB-46),
A-498(HTB-44) and 786-0 (CRL-1932) were obtained from the
American Type Culture Collection (Manassas, VA, USA).
RCC10RGB (10RGB), OS-RC2 and TUHR4TKB (4TUHR) were
purchased from RIKEN Cell Bank (Tsukuba Science City, Tokyo,
Japan). The OCUU1 and OCUU3 RCC cell lines were established
in our laboratory from Japanese RCC patients. Cell lines were
maintained in Dulbecco’s modified Eagle’s medium (Sigma,
St. Louis, MO, USA) supplemented with 10% foetal bovine serum
(HyClone, Logan, UT, USA), 100Uml
–1 of penicillin and
100mgml
–1 of streptomycin (Gibco, New York, NY, USA) at
371C in a humidified atmosphere containing 5% CO2.
Antibodies
Rabbit polyclonal anti-NUB1 antibody was obtained from Biomol
(Plymouth Meeting, PA, USA). Rabbit polyclonal anti-NEDD8
antibody was generated by immunisation with a glutathione
S-transferase-fusion protein of human NEDD8, followed by affinity
purification (Kamitani et al, 2001). Mouse monoclonal anti-cyclin
D1 and anti-cyclin E antibodies were obtained from Thermo
Fisher Scientific (Cheshire, UK). Mouse monoclonal anti-p21
and anti-p53 antibodies were purchased from Cell Signaling
Technology (Beverly, MA, USA). Mouse monoclonal anti-p27
antibody was from BD Biosciences Pharmingen (San Diego, CA,
USA). Mouse monoclonal anti-CDK2 and anti-CDK4 antibodies
were from Medical & Biological Laboratories (Nagoya, Japan).
Mouse monoclonal anti-b-actin antibody was from Abcam
(Cambridge, UK).
Cell-proliferation assay
Cells (3–5 10
3 cells per well) were incubated in 24-well culture
plates (Corning Inc., New York, NY, USA) in 500ml of medium
with or without 1000Uml
–1 of IFN-a (Dainippon Sumitomo
Pharma Inc., Tokyo, Japan). After culturing for 24, 48, 72, 96 or
120h, the supernatant was removed, and cell-growth inhibition
was determined using water-soluble tetrazolium salt (WST-1)
assay (Dojindo Laboratories, Kumamoto, Japan) according
to the manufacturer’s instructions. Absorbance was measured at
450nm using a microplate reader. All assays were carried out in
triplicate.
Real-time PCR analysis of NUB1
Total RNA was extracted from RCC cells using an RNAqueous kit
(Ambion Inc., Austin, TX, USA) in accordance with the
manufacturer’s instructions and reverse transcribed into cDNA
with random hexamers using a high-capacity cDNA reverse
transcription kit (Applied Biosystems, Foster City, CA, USA).
The cDNA was quantified by real-time PCR using the Prism 7300
Sequence Detection System (Applied Biosystems). The PCR primers
and TaqMan probes for NUB1 (assay ID: Hs00211567_m1, Applied
Biosystems) were purchased from Applied Biosystems. b-actin
(assay ID: 4333762-0711022, Applied Biosystems) was used as the
internal control for data normalisation.
Western blotting
Cells were harvested and whole-cell lysates were prepared
using the PRO-PREP protein extraction solution (iNtRON
Biotechnology, Gyeonggi-do, Korea) in accordance with the
manufacturer’s instructions. Protein concentrations of samples
were determined by the bicinchoninic acid protein assay
(BioRad, Hercules, CA, USA). Protein samples (20mgo fe a c h
protein) were treated at 501C for 1h in 2% SDS-treating solution
containing 5% b-mercaptoethanol and separated in 10% SDS–
polyacrylamide gels and transferred onto nitrocellulose mem-
branes. Membranes were blocked for 1h at room temperature
with Tris-buffered (TBS) containing 0.05% Tween 20 and 5%
non-fat dried milk, and probed overnight at 41C with primary
antibodies under manufacturer-recommended conditions.
Immunoblots were washed with TBS containing 0.05% Tween
20 and 1% non-fat milk and incubated with secondary antibodies
conjugated with horseradish peroxidase against mouse IgG
or rabbit IgG (Santa Cruz Biotechnology, Santa Cruz, CA, USA)
for 1h at room temperature. Immunoreactive proteins were
visualised using the ECL detection system (Pierce, Rockford, IL,
USA). Each western blot analysis was performed in triplicate.
Apoptosis analysis
The generation of FLAG-NUB1 in pcDNA3 has been described
(Tanaka et al, 2003). Cells were transfected with 6mg of pcDNA3/
FLAG-NUB1 or pcDNA3 (control) using 18ml of Fugene 6 reagent
(Roche, Mannheim, Germany) according to the manufacturer’s
protocol. All transfections were carried out in a condition with
serum. The transfectants were stained 24h after transfection using
the APO-DIRECT kit (BD) in accordance with the manufacturer’s
instructions. In brief, cells were washed in PBS and resuspended in
1% (w/v) paraformaldehyde in PBS. After incubation on ice,
aliquots of cells were centrifuged and resuspended in 70% (v/v)
ice-cold ethanol. The cell suspensions were incubated in staining
solution containing fluorescein isothiocyanate-dUTP, terminal
deoxynucleotidyl transferase enzyme and reaction buffer for 3h
at 371C. After washing with rinse buffer, the treated cells were
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Figure 1 Growth inhibition of nine renal cell carcinoma (RCC) cell lines after interferon alpha (IFN-a) treatment. As described in the Materials and
Methods section, the number of viable RCC cells with or without 1000IUml
–1 IFN-a treatment for 0, 24, 48, 72, 96 or 120h was determined by
water-soluble tetrazolium salt (WST-1) assay. (A) Values measured at 0h with or without IFN-a in each cell line were defined as 1. Three individual
experiments were performed. (B) Values measured after 72h without IFN-a in each cell line were defined as 1 (control). Results are expressed as
means±s.d. *Po0.05 compared with the control (Student’s t-test, n¼3).
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analysed with a FACSCalibur flow cytometer with CellQuest
software (BD Biosciences, Mountain View, CA, USA).
Cell-cycle analysis
Cells were transfected with pcDNA3/FLAG-NUB1 or pcDNA3
(control) as described above. After 16h, the cells were harvested
and stained with propidium iodide using Cycle Test plus (BD
Biosciences) according to the manufacturer’s protocol. Samples
were placed on ice and immediately analysed on FACSCalibur with
ModFit LT ver. 2.0 software (BD Bioscience) to separate G0/G1, S,
G2/M and hypodiploid nuclei.
NUB1 silencing using siRNAs
The NUB1 short interfering RNAs (siRNAs) and negative control
siRNAs were purchased from Applied Biosystems (catalogue no.
AM16708A and AM4611, respectively). Each siRNA was transfected
into subconfluent cells using Lipofectamine 2000 (Invitrogen Life
Technologies, Carlsbad, CA, USA) according to the manufacturer’s
instructions. At 72h after transfection, the transfected cells were
harvested, followed by western blotting or viable-cell counting.
Statistical analysis
Statistical analysis was performed with JMP 7.0 software. (SAS
Institute, Cary, NC, USA). Data were expressed as means±s.d.
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Figure 2 Effects of interferon alpha (IFN-a) treatment on NEDD8 ultimate buster 1 (NUB1) mRNA expression levels in renal cell carcinoma (RCC) cell
lines. (A) Nine RCC cell lines were treated with or without 1000IUml
–1of IFN-a for 6h. The NUB1 expression levels of all samples were then determined
using Taqman real-time PCR. Three individual experiments were performed. Values are means±s.d. of the gene expression level relative to that in the
control, given an arbitrary value of 1. *P o0.05 (Student’s t-test, n¼3). (B) IFN-a-sensitive (ACTHN, OCUU3) and -resistant (A498, caki-1) RCC cell lines
were incubated for 19h with various concentrations of IFN-a as indicated. NUB1 expression levels were determined by the same method as above.
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t-test and the correlation between growth inhibition and NUB1
induction by IFN-a was assessed by regression analysis.
RESULTS
IFN-a responsiveness of RCC cell lines
A498, caki-1 and 10RGB cells were almost resistant to IFN-a-
mediated cell-growth inhibition compared with other cell lines. In
other cell lines, growth was reduced to B70–80% of that in
controls after culture for 72h (Figure 1B). The A498, caki-1 and
10RGB cell lines were thus considered to be IFN-a resistant,
whereas other cell lines were considered to be IFN-a sensitive.
IFN-a induces expression of NUB1 messenger RNA in
IFN-a-sensitive RCC cell lines
The induction rates of NUB1 mRNA in IFN-a-resistant cell lines,
such as A498 and caki-1, were much lower than those of other cell
lines (Figure 2A). In IFN-a-sensitive cell lines, such as OCUU3 and
ACHN, levels of NUB1 mRNA induced by IFN-a were increased in
a dose-dependent manner (Figure 2B, upper panel). In contrast,
levels of NUB1 mRNA were not changed significantly by treatment
with IFN-a in IFN-a-resistant cells, such as A498 and caki-1
(Figure 2B, lower panel).
Positive correlation between IFN-a-induced growth
inhibition and IFN-a-induced protein expression of NUB1
Protein expression of NUB1 in both IFN-a-sensitive and -resistant
cell lines was determined by western blot analysis using an
anti-NUB1 antibody. IFN-a induced protein expression of NUB1 in
seven RCC cell lines (786-0, OCUU3, 10RGB, OS-RC2, OCUU1,
ACHN and 4TUHR) but not in caki-1 cells (1.18-fold) or A498 cells
(1.06-fold). It is noteworthy that IFN-a induced NUB1 protein in
IFN-a-sensitive cell lines, but not in IFN-a-resistant cell lines
(except for 10RGB) (Figures 3A and B). Next, single linear
regression analysis revealed that levels of NUB1 induction by
IFN-a tended to predict responses to IFN-a. This tendency was not
statistically significant when all RCC cell lines were considered
(P¼0.09 and R
2¼0.34). However, it was significant when 10RGB
was omitted from the analysis (Po0.01 and R
2¼0.74) (Figure 3C).
Overexpression of NUB1 induces apoptosis in A498
RCC cells
A498 cells, in which NUB1 was not induced by IFN-a, were
transfected with pcDNA3/FLAG-NUB1 or pcDNA3 (control), and
an apoptosis assay was performed by flow cytometry (FCM) 24h
after the transfection. Western blot analysis using the anti-NUB1
antibody revealed that expression level of NUB1 protein in A498
cells transfected with pcDNA3/FLAG-NUB1 was almost three times
more than that in control mock cells (Figure 4A). Moreover, the
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overexpressed FLAG-NUB1, underwent apoptosis (Figures 4B–D).
We also conducted the same analysis with overexpression of
FLAG-NUB1-long (NUB1L), an alternative splicing variant, and
obtained the same results under these conditions as with
FLAG-NUB1 (data not shown).
Overexpression of NUB1 alters cell cycle with S-phase
arrest through cell-cycle regulator proteins
To examine the process associated with the apoptotic effect of
NUB1, we initially performed cell-cycle analysis in A498 cells
transfected with pcDNA3/FLAG-NUB1 or empty control vector.
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Figure 4 Overexpression of NEDD8 ultimate buster 1 (NUB1) induces apoptosis in A498 cells. A498 cells were transiently transfected with pcDNA3
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while decreasing those in G0/G1 and G2/M phases, compared with
the control (Figure 5A). Next, we examined the cell-cycle regulator
proteins that were involved in the S-phase transition induced by
NUB1 overexpression. Western blot analysis revealed the
expression levels of cyclin E and p27 to be increased in A498
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Figure 5 Effects of NEDD8 ultimate buster 1 (NUB1) overexpression on cell-cycle transition in A498 cells. A498 cells transfected with pcDNA3
(control) or pcDNA3/FLAG-NUB1 were harvested 16h after transfection and stained with propidium iodide (PI) as described in the Materials and Methods
section. (A) The percentage of cells in each phase of the cell cycle was analysed by flow cytometry. Relative fluorescence intensities in a two-dimensional
fluorescence-activated cell sorting (FACS) profile (ModFit LT software) in the control (left) or NUB1-overexpressing A498 cells (right) are presented. (B)A s
noted in the Materials and Methods section, cells were harvested 48h after transfection and total cell lysates were prepared and analysed by western blot
analysis using antibodies directed against the indicated proteins. Each experiment was performed in triplicate. The expression levels of p27 and cyclin E were
normalised by the b-actin level and presented as the relative fold compared with the control. Data values were presented as means±s.d.
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control cells (Figure 5B). There were no significant changes in the
expression levels of other cell-cycle regulators. Moreover, over-
expression of NUB1 decreased the expression of NEDD8 in A498
cells (Figure 5B). These results were reproduced in the same
analyses with overexpression of FLAG-NUB1L or caki-1 cells (data
not shown).
Downregulation of NUB1 promotes cell proliferation and
suppresses IFN-a-induced inhibition of cell growth
We also investigated the effect of NUB1 knockdown on cell growth
in RCC cells using the RNA interference technique. The efficiency
of siRNA against NUB1(siNUB1) was determined by the extent of
knockdown of NUB1 protein as compared with the expression
level of endogenous NUB1 in control cells using western blot
analysis. In A498 cells transfected with siNUB1, the amount of
NUB1 protein was reduced to o10% of that in control A498 cells
(Figure 6A a). Knockdown of NUB1 clearly enhanced A498 cell
growth, compared with control cells (Figure 6A b). Next, in IFN-a-
treated 4TUHR cells transfected with siNUB1, the amount of NUB1
protein was reduced to o10% of that in control 4TUHR cells
treated with IFN-a (Figure 6B a). The number of control 4TUHR
cells treated with IFN-a was decreased to B50% of that in
control 4TUHR cells treated without IFN-a. Knockdown of NUB1
partially suppressed IFN-a-induced inhibition of 4TUHR cells
(Figure 6B b).
DISCUSSION
NEDD8 has been reported to conjugate to a limited number of
target proteins, including cullin family members (Cul-1, -2, -3, -4A,
-4B and -5), von Hippel–Lindau protein (pVHL), murine double
minute 2 (Mdm2), p53 and p73 (Kipreos et al, 1996; Wada et al,
1999; Read et al, 2000; Stickle et al, 2004; Xirodimas et al, 2004;
Watson et al, 2006). Indeed, the NEDD8 conjugation system
controls many biological events, including cell-cycle progression,
tumorigenesis and neurodegeneration (Podust et al, 2000; Mori
et al, 2005; Chairatvit and Ngamkitidechakul, 2007; Salon et al,
2007). Therefore, NUB1 is potentially involved in important
biological functions through regulation of the NEDD8 conjugating
system.
However, to our knowledge, there are no reports showing the
basic mechanisms underlying the anti-tumour effects of NUB1 on
cancer cells. First, we investigated whether NUB1 is induced by
IFN-a in nine different human RCC cell lines. Expression levels of
NUB1 mRNA and protein were upregulated by IFN-a in seven RCC
cell lines, namely, ACHN, OS-RC-2, OCUU1, OCUU3, 786-0,
4TUHR and 10RGB. Importantly, growth of these cell lines, except
for 10RGB, was significantly inhibited by IFN-a. A498, caki-1 and
10RGB were essentially resistant to IFN-a treatment. Most notably,
in both A498 and caki-1cells, NUB1 expression levels were not
significantly changed by IFN-a. We demonstrated a positive
significant correlation between IFN-a-induced NUB1 expression
and IFN-a-induced cell growth inhibition in six out of the seven
IFN-a-sensitive cell lines, that is, in all but 10RGB. The slow
proliferation of 10RGB cells might contribute to the lack of
difference in cell viability between cells treated with IFN-a and
untreated cells (as shown in Figure 1A). Next, we demonstrated
that overexpression of NUB1 in two cell lines, A498 and caki-1,
triggered cell-cycle alterations and apoptosis. Furthermore, we
showed that NUB1 overexpression increased the cell population in
the S phase during the cell cycle and upregulated two rate-
determining components for cell-cycle transition (cyclin E and
p27) and downregulated the expression of NEDD8. Previous
studies defined various components in the fundamental pathways
that regulate G1–S progression, including cyclin D, cyclin E and
their associated cyclin-dependent protein kinases (CDKs), includ-
ing CDK4/6 and CDK2 (Koff et al, 1992; Sherr and Roberts, 1999).
p27 is one of the CDK inhibitors that function as a major brake to
the cell cycle and also induce apoptosis (Polyak et al, 1994; Vlach
et al, 1996). Biologically, p27 mainly inhibits the activity of cyclin
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Figure 6 Knockdown of NEDD8 ultimate buster 1 (NUB1) expression
promotes cell growth and suppresses interferon alpha (IFN-a)-induced
inhibition of cell proliferation . (A, a) A498 cells transfected with negative
control short interfering RNA (siRNA) (left) or NUB1 siRNA (right) were
harvested 72h after transfection and total cell lysates were analysed by
western blotting using an anti-NUB1 antibody to evaluate the efficacy of
NUB1 siRNA. (B, a) IFN-a-untreated 4THUR cells transfected with
negative control (left), 4THUR cells, which were simultaneously treated
with 1000IUml
–1 IFN-a for 72h, transfected with negative control
(middle) or NUB1 siRNA (right) were followed up by the aforementioned
analysis. (A, b; B, b) Viable cells were counted and the numbers were
normalised on the basis of negative control cells. Three individual
experiments were performed and the means±s.d. are presented;
*Po0.05 compared with the control (Student’s t-test, n¼3).
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sE–CDK2 complexes and thereby blocks progression from the G1
to the S phase (Sheaff et al, 1997). Interestingly, both p27 and
cyclin E are major targets for the ubiquitination catalysed by the
SCF complex. Thus, it is possible that NUB1 causes the S-phase
transition and apoptosis, both of which are attributable to the
inhibition of ubiquitination for p27 and cyclin E through a
negative regulation of the NEDD8 conjugation system. Moreover,
overexpression of NUB1L, an alternative splicing variant, induced
S-phase arrest and apoptosis in the same series of experiments. As
NUB1L also downregulates NEDD8 expression (Tanaka et al,
2003), one can speculate that NUB1L controls the expression levels
of cyclin E and p27 through inhibition of NEDD8 expression, as
well as that of NUB1. In addition, NUB1L has been reported to
bind to FAT10 (one of the ubiquitin-like proteins), which induces
apoptosis and regulates the cell cycle, and target FAT10 for
degradation of 26S proteasome (Raasi et al, 2001; Hipp et al, 2004;
Lim et al, 2006). In our used RCC cells, we could not detect an
expression of FAT10 protein by western blotting (data not shown).
It is possible that FAT10 does not have a crucial role in these RCC
cells. Furthermore, some reports have shown that IFN-a induces
S-phase arrest and apoptosis in liver cancer cell lines (Matsumoto
et al, 2005; Yano et al, 2006). The positive correlation between
NUB1 induction and suppression of cell growth by IFN-a
indicates that NUB1 could be a key molecule in IFN-a-induced
cell-cycle arrest and apoptosis in human RCC cells. Further-
more, knockdown of NUB1 remarkably increased proliferation
in IFN-a-resistant A498 cells and partly suppressed IFN-a-
induced inhibition of cell proliferation in IFN-a-sensitive 4TUHR
cells.
On the basis of these experimental results, an altered expression
of NUB1, which functions as a negative cell-cycle regulator, not
only possibly correlates with IFN-a-induced anti-mitogenic action,
but might also yield anti-cancer effects against advanced RCC,
against INFa-resistant RCC as well.
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